Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL1155758 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL94267 | 0.90 | ALDH1A1 (0.70) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19971558 | 0.82 | ALDH1A1 (0.73) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Phenazine SCHEMBL28375190 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP2C19KMT2ARAB9A | |
| Phenazine-1-Carboxylic Acid SCHEMBL27752237 | 0.78 | ALDH1A1 (0.93) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Phenazine-1-Carboxylic Acid SCHEMBL29370801 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Phenazine-1-Carboxylic Acid SCHEMBL122864 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Phenazine-1-Carboxylic Acid SCHEMBL28160016 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Phenazine-1-Carboxylic Acid SCHEMBL27884214 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Maleic Acid SCHEMBL28811648 | 0.78 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2070 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-20190145960-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-05-16 | — | — | US | claimed |
| EP-3470536-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2019-04-17 | — | — | EP | claimed |
| US-10184933-B2 | Compositions, systems and methods for gene expression noise drug screening and uses thereof | The J. David Gladstone Industries (US) | 2019-01-22 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20160245796-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-08-25 | — | — | US | claimed |
| EP-3052662-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2016-08-10 | — | — | EP | claimed |
| EP-1349835-B1 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | EUTHYMICS BIOSCIENCE INC (US) | 2016-03-30 | — | — | EP | claimed |
| US-20150148256-A1 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-05-28 | — | — | US | claimed |
| WO-2002066427-A2 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | DOV PHARMACEUTICAL, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-6372919-B1 | SUBSTANTIALLY FREE OF CORRESPONDING (-)-ENANTIOMER | DOV PHARMACEUTICAL, INC. | 2002-04-16 | — | — | US | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |